Date: 2015-08-30
Type of information: Licensing agreement
Compound: technologies for induced pluripotent stem cell (iPS cell) research
Company: STEMCELL Technologies (Canada) iPS Academia Japan (Japan)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: * On August 25, 2015, STEMCELL Technologies has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialize iPS Academia Japan, Inc.’s patented technologies for induced pluripotent stem cell (iPS cell) research. This agreement will enable STEMCELL Technologies to develop, manufacture, and distribute products that are optimized for cellular reprogramming. This further expands STEMCELL’s extensive portfolio of products for hPSC research, which includes ReproTeSR™ and TeSR™-E7™ media for reprogramming, the TeSR™ family of maintenance media, and the STEMdiff™ product line for robust and reliable differentiation to various cell lineages. The patents related to iPS cell technologies licensed by iPS Academia Japan are the result of the groundbreaking research of Professor Shinya Yamanaka of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, Japan.
Financial terms:
Latest news:
